Phase IB/II Open-label Single Arm Study to Evaluate Safety and Efficacy of Tucatinib in Combination With Palbociclib and Letrozole in Subjects With Hormone Receptor Positive and HER2-positive Metastatic Breast Cancer
Phase of Trial: Phase I/II
Latest Information Update: 16 Nov 2018
At a glance
- Drugs Letrozole (Primary) ; Palbociclib (Primary) ; Tucatinib (Primary)
- Indications Breast cancer
- Focus Adverse reactions; Therapeutic Use
- Acronyms TULiP
- 05 Nov 2018 Planned End Date changed from 1 Oct 2018 to 1 Oct 2020.
- 05 Nov 2018 Planned primary completion date changed from 1 Oct 2018 to 1 Oct 2019.
- 31 Aug 2018 Biomarkers information updated